Open AccessANGPTL3 as therapeutic target
Author(s) -
Sander Kersten
Publication year - 2021
Publication title -
current opinion in lipidology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.412
H-Index - 124
eISSN - 1473-6535
pISSN - 0957-9672
DOI - 10.1097/mol.0000000000000789
Subject(s) - dyslipidemia , triglyceride , pcsk9 , medicine , disease , monoclonal antibody , endocrinology , lipoprotein lipase , lipoprotein , antibody , cholesterol , bioinformatics , pharmacology , biology , immunology , ldl receptor , adipose tissue
Elevated LDL-C and triglycerides are important risk factors for the development of atherosclerotic cardiovascular disease. Although effective therapies for lipid lowering exist, many people do not reach their treatment targets. In the last two decades, ANGPTL3 has emerged as a novel therapeutic target for lowering plasma LDL-C and triglycerides. Here, an overview of the recent literature on ANGPTL3 is provided, focusing on the therapeutic benefits of inactivation of ANGPTL3 via monoclonal antibodies, antisense oligonucleotides, and other more nascent approaches. In addition, the potential mechanisms by which ANGPTL3 inactivation lowers plasma LDL-C are discussed.